Humacyte, Inc. (HUMA)
(Delayed Data from NSDQ)
$1.53 USD
-0.04 (-2.55%)
Updated Sep 17, 2025 04:00 PM ET
After-Market: $1.53 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
HUMA 1.53 -0.04(-2.55%)
Will HUMA be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for HUMA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for HUMA
Is It Worth Investing in Humacyte, Inc. (HUMA) Based on Wall Street's Bullish Views?
Humacyte, Inc. (HUMA) Reports Q2 Loss, Misses Revenue Estimates
HUMA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Humacyte, Inc. (HUMA) Stock Dips While Market Gains: Key Facts
Humacyte, Inc. (HUMA) Suffers a Larger Drop Than the General Market: Key Insights
Humacyte, Inc. (HUMA) Stock Dips While Market Gains: Key Facts
Other News for HUMA
20 Day Moving Average Support appears for HUMA after 2.61% move
Is HUMA ready to move higher? Crossed Above 20 Day Moving Average shows up after advancing 4.08%
HUMA Stock Maintains 'Buy' Rating by D. Boral Capital | HUMA Stock News
Humacyte (HUMA) Publishes Promising Results for Symvess in Treating Vascular Complications
Humacyte announces publication of outcomes for patients treated with Symvess